Madrigal Pharmaceuticals, Inc.
MDGL· Nasdaq
Released Oct 31, 2024, before the open
10-Q filed Oct 31, 2024, 31 days after period end · 0001628280-24-044445
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $62.18M | $0.00 | $0.00 | $0.00 |
| Net Income | -$106.96M | -$98.74M | -$81.20M | -$63.10M |
| EPS Diluted |
Madrigal Pharmaceuticals, Inc. · CIK 1157601 · Engraved from SEC EDGAR
| -$4.92 |
| -$5.34 |
| -$4.75 |
| -$3.79 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.